Skip to main content
. Author manuscript; available in PMC: 2021 Oct 27.
Published in final edited form as: ACS Nano. 2020 Sep 25;14(10):13343–13366. doi: 10.1021/acsnano.0c05194

Figure 8. The dual-delivery liposome significantly improved survival outcome in the CT26 colon cancer model.

Figure 8.

The experimental schedule is identical to the efficacy study in Figure 6, except that the animals were sacrificed when approach end-of-life criteria, as determined by the approved animal protocol. (A) Kaplan-Meier analysis to show that L-MTO significantly improved survival when compared to the untreated controls (Log-rank/Mantel-Cox test, n = 8, Chi-square 16.55, ****p < 0.0001). IND co-delivery with MTO leads to a highly significant increase in animal survival over L-MTO treatment, with 1 out of 8 mice ended up tumor-free. (Log-rank/Mantel-Cox test, n = 8, Chi-square 11.62, ***p = 0.0007) (B) Averaged tumor growth curves to show that L-MTO and L-MTO/IND were equally efficient at inhibiting tumor growth by day 23 compared to the untreated control (Brown-Forsythe ANOVA test F(2, 7.8) = 24.01, ***p= 0.005, post hoc = Dunnett’s T3 test: **p = 0.0063 and 0.0035 for L-MTO vs. UT and L-MTO/IND vs. UT, respectively. L-MTO versus L-MTO/IND p = 0.1081 at day 23). However, from day 24 onwards, the co-delivery L-MTO/IND liposome was significantly more effective than L-MTO through the duration of the study. (unpaired t-test day 24 t(14) = 2.418, *p = 0.0299; day 25 t(14) = 2.726, *p = 0.0164; day 28 t(14) = 3.021, **p = 0.0092; day 38 t(14) = 3.675, **p = 0.0025) (C) The corresponding spaghetti tumor growth curves confirm that the most significant tumor growth inhibition was obtained by L-MTO/IND co-delivery when compared to L-MTO and untreated controls.